



BIOGRAPHY, PIERO OLLIARO, MD, PHD

Dr PIERO OLLIARO is the head of intervention and implementation research at TDR. He has been with TDR since 1993, covering different functions in research and capacity building. Before joining TDR he had worked as general practitioner, hospital consultant, and as researcher in academia and the pharmaceutical private sector.

Through this range of experiences he has acquired skills spanning laboratory, pharmacology, clinical and field research in several poverty-related infectious diseases. Some of his main achievements include contributions to: the establishment of artemisinin combination therapy and the development of artesunate-amodiaquine and artesunate-mefloquine for malaria; the development of rifabutin and studies of gatifloxacin for tuberculosis; paromomycin and various combination therapies for visceral leishmaniasis, paromomycin for cutaneous leishmaniasis; the provision of evidence for various policy and guidelines through systematic reviews; the establishment of the Drug for Neglected Diseases initiative (DNDi) and the Europe and Developing Countries Clinical Trial Partnership (EDCTP). Current areas of work include helminths and dengue.

He is the author of 255 papers, has chaired and participated in several international symposia and has been a member or chair of various scientific committees and study drug and safety monitoring boards. He is an editor of the Cochrane Infectious Diseases Group.

Honorary affiliations include a visiting professorship with Oxford University and a research fellowship with the Liverpool School of Tropical Medicine since 2001. He has been appointed to the Newton-Abraham visiting professorship at the University of Oxford for 2014-2015.

Dr Piero Olliario, Italian, received his MD, PhD, and post-graduation in infectious diseases at the University of Pavia in Italy, and his HDR (habilitation à diriger les recherches) at the University Joseph Fourier, Grenoble in France. He is a member of the French Academy of Medicine.